April 24 - 27, 2025 | American Physiology Summit 2025 April 25 - 30, 2025 | AACR Annual Meeting 2025 May 12 - 15, 2025 | PEGS 2025 May 20 - 22, 2025 | SLAS Europe 2025 June 16 - 19, 2025 | BIO International

June 2022 "Ottawa, Canada, May 10, 2022 — Orion Biotechnology Canada Ltd, a drug discovery and development important new data at both LSX World Congress and TIDES USA 2022 conference, taking place this week – May

Purpose-driven exposure strategies enhance detection Unique pharmacokinetics may be required for robust

(May 22 - 26, 2023) 2nd LEAPS Meets Life Sciences Conference. (May 14 - 19, 2023) 8th and final ERNEST Meeting in Crete. (May 3 - 7, 2023).

We propose that Pc(4-4) may serve as a powerful drug not only toward PAR-expressing tumors but also for Pc(4-4) may become a promising candidate for future therapeutic cancer treatment."

(May 22 - 26, 2023) 2nd LEAPS Meets Life Sciences Conference. (May 14 - 19, 2023) 8th and final ERNEST Meeting in Crete. (May 3 - 7, 2023).

We then demonstrate that sub-cellular localization and alternative signaling pathways may be responsible Our results suggest that strategies to selectively target OGR1 expression may represent a novel therapeutic

Specifically, the ideas discussed cover the complex pleiotropic behaviors of GPCRs and how these may schizophrenia Single nucleotide variations encoding missense mutations in G protein-coupled receptors may

The takeaway:  what looks like pharmacology failure may be a systems problem .

- 27, 2025 | American Physiology Summit 2025 NEW April 25 - 30, 2025 | AACR Annual Meeting 2025 NEW May 12 - 15, 2025 | PEGS 2025 NEW May 20 - 22, 2025 | SLAS Europe 2025 NEW June 16 - 19, 2025 | BIO International

May 2022 Sosei Heptares and Kallyope Enter Collaboration to Identify and Validate Novel Gastrointestinal the development of new gastrointestinal therapeutics Tokyo, Japan, Cambridge, UK and New York, USA – May

May 2022 "MONTREAL (CANADA) – May 17, 2022 – Inversago Pharma Inc.

Behind Every Probe Is a Partnership While the final product may arrive neatly packaged, the journey behind

This approach reveals: Hidden target overlap New therapeutic hypotheses “Off-target” effects that may They are mainstream pharmacology.

May 2022 "We are thrilled to announce that our co-founder Margaux Duchamp has been selected as a 30 under

Pain may associate with inflamed tissue characterized by acidic pH. typically have a protonated amino group that contributes to receptor binding, and the functioning of GPCRs may

Curves that “look fine” may hide non-equilibrated systems. The fix?

(May 22 - 26, 2023) 2nd LEAPS Meets Life Sciences Conference. (May 14 - 19, 2023) 8th and final ERNEST Meeting in Crete. (May 3 - 7, 2023).

receptors (SSTs) are class A GPCRs abundantly expressed in pituitary tumors where they represent the main Moreover, whether octreotide or pasireotide may play modulatory effects and whether FLNA may participate

Slopes <1  may reveal allosteric modulation , where the antagonist binds at a secondary site.

Studies of GPR21 knock-out mice indicated that GPR21 may be involved in promoting macrophage migration

(May 22 - 26, 2023) 2nd ERNEST Training School. (February 20 - March 3, 2023). GEM2023. (May 3-7, 2023). The Illuminating the Understudied Druggable Proteome Conference.

Food and Drug Administration (FDA) that the study may proceed.

Despite a better understanding of the disease, the current mainstay of treatment cannot modify pathogenesis provide insights into some novel strategies, including allosterism and the targeting of oligomers, which may

upon activation than previously solved class A GPCR-Gi complex structures is observed in CX3CR1, which may

The recognition that GPCRs may physically interact with each other has led to the hypothesis that their distinct cell compartments along the plasma membrane where confined increases in second messengers may

Ligands eliciting biased signalling may constitute better drugs with higher efficacy and fewer adverse

Despite a better understanding of the disease, the current mainstay of treatment cannot modify pathogenesis provide insights into some novel strategies, including allosterism and the targeting of oligomers, which may

August 2022 "Bone remodeling is precisely regulated mainly by osteoblasts and osteoclasts. Considering that synaptamide is the endogenous metabolite of DHA, we hypothesized that DHA may inhibit

PLC activities self-regulate the expression of PLC isozymes with the suggestion that PLC activities may